This site is intended for health professionals only

DH limits NHS pharma spend

DH limits NHS pharma spend

|

The NHS has negotiated a limit on the amount to be spent on branded medicines, with all excess paid by the pharmaceutical industry. 

The new Pharmaceutical Price Regulation Scheme (PPRS), agreed with the Association of the British Pharmacuetical Industry, will provide “predictability and certainty” on the spend for branded medicines, the Department of Health (DH) has claimed. 

According to DH, the scheme will encourage the use of innovative and cost effective treatments, strengthening Britain’s life science sector. 

Lord Earl Howe, Health Minister, said: “This agreement ensures NHS patients will receive the most effective, advanced medicines in the world while managing the cost. I’m delighted that today we have published the full details of the new pricing scheme.

“UK pharmaceutical companies have responded to the challenges we face as a country, both in terms of the increased demand for medicines and pressure on public spending. I hope in return we have given them the certainty and backing they need to flourish as a sector both here and in the global market.” 

|

Comments

ok , will admit i havent read all the details but seems to me that the doh has guaranteed huge profit margins for these companies with no gurantee that money will be invested in further research or even into areas of enourmous need like new antimicrobials. rather than mega expensive orphan drugs or biologicals of enormous cost per QALY.
In addition the negotiations into extension of patent protection means that these companies could equally just slash investment for 25 years and make even bigger profits In the meantime in GP land we are being told to switch drugs to save 50p a month per patient.
On the other hand perhaps we can now switch all our prescribing into proprietary brands.
Does this explain the recent advice to switch epilepsy drugs to brand name prescribing?

Ads by Google